

IN A NUTSHELL



# Traffic light at DSB–transit regulation between gene transcription and DNA repair

Stefania Modafferi<sup>1,[2](https://orcid.org/0000-0002-5669-860X)</sup>  $\bullet$ , Francesca Esposito<sup>1,3</sup>, Sara Tavella<sup>1,[4](https://orcid.org/0000-0002-4993-5283)</sup>, Ubaldo Gioia<sup>1,4</sup>  $\bullet$  and Sofia Francia<sup>1,4</sup>

1 Istituto di Genetica Molecolare "Luigi Luca Cavalli Sforza"– Consiglio Nazionale delle Ricerche, Pavia, Italy

2 PhD Program in Biomolecular Sciences and Biotechnology (SBB), Istituto Universitario di Studi Superiori (IUSS), Pavia, Italy

3 PhD Program in Genetics, Molecular and Cellular Biology (GMCB), University of Pavia, Pavia, Italy

4 IFOM-ETS – The AIRC Institute of Molecular Oncology, Milan, Italy

#### Correspondence

U. Gioia and S. Francia, Istituto di Genetica Molecolare, CNR – Consiglio Nazionale delle Ricerche, Pavia 27100, Italy Tel: +39 0382 546325 E-mail: [ubaldo.gioia@igm.cnr.it](mailto:ubaldo.gioia@igm.cnr.it); [sofia.](mailto:sofia.francia@igm.cnr.it) [francia@igm.cnr.it](mailto:sofia.francia@igm.cnr.it)

(Received 27 February 2024, revised 12 August 2024, accepted 15 August 2024)

doi:10.1002/1873-3468.15024

Edited by Donata Orioli

Transcription of actively expressed genes is dampened for kilobases around DNA lesions via chromatin modifications. This is believed to favour repair and prevent genome instability. Nonetheless, mounting evidence suggests that transcription may be induced by DNA breakage, resulting in the local de novo synthesis of non-coding RNAs (ncRNAs). Such transcripts have been proposed to play important functions in both DNA damage signalling and repair. Here, we review the recently identified mechanistic details of transcriptional silencing at damaged chromatin, highlighting how post-translational histone modifications can also be modulated by the local synthesis of DNA damage-induced ncRNAs. Finally, we envision that these entangled transcriptional events at DNA breakages can be targeted to modulate DNA repair, with potential implications for locus-specific therapeutic strategies.

Keywords: DNA damage response; DNA double strand break; DNA repair; non-coding RNAs; transcription

#### DNA damage-induced transcriptional silencing

Transcriptional repression of genes in cis to Double Strand Breaks (DSB) is a well-documented event occurring upon DNA breakage [[1,2\]](#page-9-0). This finely tuned phenomenon has been referred to as Damage Induced transcriptional Silencing in Cis (DISC) [[3\]](#page-9-0). DISC is dependent on the activation of DNA damage response (DDR) apical kinases, Ataxia-telangiectasia mutated (ATM) [[1,3\]](#page-9-0) but also DNA-dependent protein kinase, catalytic subunit (DNA-PKcs) [[4](#page-9-0)], as demonstrated by the fact that the inhibition of their kinase activity allows transcriptional recovery even in the presence of DNA breaks  $[1,4,5]$ . Thus, the

dampening in transcription of a damaged gene is, surprisingly, not due to the physical presence of breakages on the DNA, but rather is a process actively regulated via chromatin modification. Indeed, transcriptional silencing is not restricted to the single gene carrying the break but involves several genes in the surroundings of the DSB, reaching distances of hundreds of kilobases [[1,3\]](#page-9-0). Histone post-translational modifications (PTMs) have a prominent role in chromatin regulation and indeed also DISC is achieved by extensive chromatin modification via ubiquitination, methylation, and deacetylation, which results in

#### Abbreviations

ASOs, antisense oligonucleotides; DDR, DNA damage response; DDRNA, DNA damage response RNA; dilncRNA, damage-induced long non-coding RNA; DISC, damage induced transcriptional silencing in cis; DSB, DNA double strand break; lncRNA, long non-coding RNA; ncRNA, non-coding RNA; PTM, post-translational modifications; tDDRNA, telomeric DNA damage response RNA.

<span id="page-1-0"></span>chromatin compaction and consequent stalling or eviction of the elongating RNA-Polymerase II (RNA-PII) [\[3,4,6,7\]](#page-9-0).

Upon generation of a DSB, the lesion is recognized by the sensor complex MRE11-RAD50-NBS1 (MRN) which in turn recruits ATM [\[8,9](#page-9-0)]. Following ATM activation, histone H2AX is phosphorylated on Ser139 ( $\gamma$ H2AX). The formation of  $\gamma$ H2AX enables the recruitment of downstream DDR factors such as MDC1 [[10\]](#page-9-0). Lethal malignant brain tumour-like protein 2 (L3MBTL2) is recruited at DSB by MDC1 and orchestrates the recruitments of the RING-type E3 ubiquitin ligases RNF8 and RNF168 [[11](#page-9-0)]. RNF8 ubiquitylates L3MBTL2, which in turn facilitates the recruitment of RNF168. It is in fact RNF168, and not RNF8, that catalyses the mono-ubiquitination of the histones H2A and H2AX specifically on Lys 13–15 (H2AK13,15Ub) [[12](#page-9-0)], which stimulates DNA repair through BRCA1 and 53BP1 recruitment (Fig. 1 panel 1 and Table [1\)](#page-3-0).

In most genomic loci, the maintenance of facultative heterochromatin and the consequential repression of transcription, is dependent on the activity of the Polycomb group proteins (PcGs), differentiated into two large repressive complexes, namely Polycomb Repressive Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2) [\[13](#page-9-0)]. The starting modification in transcriptional repression is the mono-ubiquitination

of histone H2A at lysine 119 (H2AK119ub1), catalysed by the PRC1 complex composed by the core catalytic subunits, the E3 ubiquitin ligase RING1A/B, in cooperation with Polycomb Group RING finger protein 4 (PCGF4 or BMI1) [\[14\]](#page-9-0). This modification can in turn promote the PRC2-dependent methylation of histone H3 on lysine 27 via Enhancer of Zeste Homo-log 1 or 2 (EZH1 or EZH2) activity [[14](#page-9-0)]. Both complexes contribute to the correct organism development by establishing and maintaining cell type-specific transcriptional programs [[15](#page-9-0)]. Also, L3MBTL2 belongs to the PcG family and interacts with the histone deacetylase domain of histone deacetylase 3 (HDAC3), thus negatively regulating transcription of target genes [[16](#page-9-0)]. Importantly, L3MBTL2 has been implicated in transcriptional repression and chromatin compaction via PRC1 [[17,18](#page-10-0)]. In addition, BMI1/RING1b-dependent H2AK119 ubiquitination has already been shown to functionally promote Non-Homologous End Joining (NHEJ) in the context of deprotected telomeres and favour repair of ionizing radiation (IR)-induced DSBs at heterochromatin loci [\[19\]](#page-10-0). Although initially the recruitment of the BMI1-PRC1 complex at individual endogenous DSBs was controversial [[20](#page-10-0)], restricting its role to clusters of DSBs, recently it has been confirmed that the BMI1-PRC1 complex catalyses H2AK119ub1 deposition also at one separate DSB to promote DISC [\[21\]](#page-10-0). Importantly, we also show in our preprint that

Fig. 1. DNA damage response (DDR) activation and Damage Induced Transcriptional Silencing in Cis (DISC) is induced at DNA double strand breaks by multiple redundant signalling pathways and coexist with de novo synthesis of damaged induced ncRNAs. Top panel: (1) Upon the generation of a double strand break (lightning), the sensor complex MRN recruits ATM to the break site [[3\]](#page-9-0). ATM phosphorylates the histone H2AX on Ser139 (known as  $\gamma$ H2AX), promoting he recruitment of the mediator factor MDC1 [[10](#page-9-0)], and the E3 ubiquitin ligase RNF8, which ubiquitinates the Polycomb factor L3MBTL2 [\[11\]](#page-9-0), anchoring the E3 ubiquitin ligase RNF168. This second Ubiquitin ligase deposits H2AK13/ 15Ub histone marks required for DNA repair factors [[12](#page-9-0)]. (2) Furthermore, ATM and Poly [ADP-ribose] polymerase 1 (PARP1 – another apical DDR factor) recruits DYRK1B to DSB. This kinase in turn recruits PBAF and STAG2 cohesin complexes to break sites, leading to chromatin compaction and gene silencing [[28,32](#page-10-0)]. (3) ATM also promotes the recruitment of the Bromodomain containing protein BRD7 to DSBs which in turn controls the activity of the chromatin-modifying complexes Polycomb group 1 and 2 (PcG) and Nucleosome Remodelling and De-Acetylase (NuRD) complexes, depositing in proximity to DNA damage repressive histone marks on chromatin [\[31](#page-10-0)]. (4) PARP1-dependent recruitment of CDYL1 allow the association of the PRC2 subunit EZH2 to DSBs, mediating the deposition of the repressive H3K27me3 histone mark at the damaged chromatin [[33\]](#page-10-0). (5) PARP1 also contributes to DISC by recruiting remodelling and splicing factor RSF1 and HDAC1, which deacetylate histones, leading to chromatin compaction and silencing [[37\]](#page-10-0). (6) Following the generation of a double strand break, RNAPII synthesizes dilncRNAs that can be then processed by DROSHA and DICER into shorter DDRNAs, necessary to foster DDR signalling [\[43,46\]](#page-11-0). Polycomb repressive complex 1 (PRC1) composed by the E3 catalytic subunit RING1A/B and the Ring finger factor BMI1, instead is known to monoubiquitinate H2A on K119, a repressive modification leading to chromatin compaction and transcriptional repression of DNA break flanking genes [[22](#page-10-0)]. In our preprint, we present data suggesting that the generation of dilncRNAs and DDRNAs might be required for the recruitment of BMI1 and transcriptional silencing at DSB. (7) Hypothetical working model showing how the different factors showed in panels 2–6 contribute to DISC at the same damaged locus. Small numbers refer to panels 2–6 described above. We propose that a dual modulation of transcription exists at DSBs. On the one hand, in the vicinity of the break, non-coding RNAs are de novo synthesized by RNAPII and further processed by DROSHA and DICER, especially at repetitive loci. On the other hand, the chromatin regions surrounding the break are compacted by histone post-translational modifications. We propose that these two apparently opposite events might be functionally linked and that histone modifiers might be also recruited at damaged chromatin by sequence specific non-coding RNAs generated upon DNA damage. Bottom panel: table indicating each factor involved in DDR, DISC and de novo synthesis. ? indicates a postulated interaction between BMI1 and dilncRNAs reported in our pre-print discussed in the text but still unpublished on peer-reviewed journal. The figure was created with [BioRender.com](http://biorender.com).



BMI1 is recruited at endogenous DSBs generated by inducible restriction enzymes and by CRISPR/Cas9 mediated cleavage [[22](#page-10-0)]. Recently, BMI1-deposited H2AK119ub1 has been shown to concomitantly inhibit RNAPII transcription and recruit to DSBs the CtIP factor, which supports resection in S-G2 cells,

<span id="page-3-0"></span>



initiating repair via the Homologous Recombination (HR) pathway [[23](#page-10-0)]. Nevertheless, H2AK119ub1 has also been involved by different studies in NHEJ in G1 cells [\[24,25\]](#page-10-0). Thus, BMI1 seems to foster DSBs repair via both HR and NHEJ. At UV-induced lesions, BMI1 has been shown to recruit the Ubiquitin Protein Ligase E3 Component N-Recognin 5 (UBR5) that negatively regulates the function of the Facilitates Chromatin Transcription (FACT) histone chaperone complex [\[6](#page-9-0)]. A canonical function of FACT is to facilitate the nucleosomal reorganization to favour transcriptional elongation of RNAPII [[26](#page-10-0)]. The ubiquitination by UBR5 transiently inhibits FACT and consequently RNAPII elongation to promote DNA repair [\[6](#page-9-0)].

At DSBs, UBR5 is retained by its interaction with the Ovarian Tumour Deubiquitinase 5 (OTUD5) [[27](#page-10-0)]. The OTUD5-UBR5 axis contributes to DISC by preventing access of elongating RNAPII to break-bearing genes. Independently from its interaction with UBR5, OTUD5 also interacts with SPT16, another component of the FACT complex. In this way, FACT activity is inhibited also in cis to DSBs and prevents RNAPII

access to damaged chromatin [[27](#page-10-0)]. In the past years, other reports suggested that DNA-PKcs activation upon DNA damage in actively transcribed genes, locally induces RNAPII ubiquitination and its proteasomal degradation by promoting the interaction of RNAPII with the HECT E3 ubiquitin ligase WWP2 (WW Domain Containing E3 Ubiquitin Protein Ligase 2) [\[4,5](#page-9-0)]. Thus, despite most studies suggest that DISC inhibits RNAPII elongation, some studies proposed that a fraction of RNAPII is actively removed from the damaged chromatin by targeting it to proteasomal degradation, even if persistent DNA damage seems to be required to activate this phenomenon [\[5](#page-9-0)].

Moreover, the serine/threonine kinase, Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1B (DYRK1B) has been recently identified as a new key factor in DISC, working downstream of ATM and shutting down transcription in the presence of DSBs. DYRK1B interacts with the Euchromatic Histone Lysine Methyltransferase 2 (EHMT2) [[28](#page-10-0)], a methyltransferase that methylates Lysine 9 in Histone H3 (a common marker of heterochromatin), leading to transcriptional repression, upon DSBs generated by radiation in mammalian cells [[29,30](#page-10-0)]. Similarly to ATM inhibition, loss of DYRK1B activity restores transcription, even if the presence of DSBs persists. Another interactor of DYRK1B is BRD7 (Bromodomain Containing 7) [\[28\]](#page-10-0), a subunit of the Polybromo-Associated BAF (PBAF) chromatin remodelling complex (Fig. [1](#page-1-0) panel 2). ATM-mediated recruitment of BRD7 at break sites promotes DISC by engaging other chromatin repressive complexes, such as PRC2 and Nucleosome Remodelling Deacetylase (NuRD) complex (Fig. [1](#page-1-0) panel 3) and promotes recruitment of several DDR factors, including MRN, BRCA1, 53BP1 and RNF168, to DNA lesions [[31](#page-10-0)]. Similar results were obtained upon depletion of the Brahma-Related Gene 1 (BRG1), the catalytic subunit of the PBAF complex [\[32\]](#page-10-0).

Also, the cohesin complex – crucial in mediating sister chromatids faithful segregation in the G2 phase of the cell cycle – has been found to function in transcriptional repression. Indeed, loss of STAG2 – a cohesin subunit – abolishes DISC  $[32]$  $[32]$ . Of note, this novel function of cohesin is not restricted to the G2 phase, but instead occurs throughout the cell cycle and is independent from its role during mitosis [[32](#page-10-0)]. Interestingly, loss of DYRK1B impairs STAG2 recruitment to laser tracks [\[28](#page-10-0)], suggesting that DYRK1B may act upstream of the cohesin complex in modulating DISC (Fig. [1](#page-1-0) panel 2).

PARP1 (poly-ADP-ribose polymerase 1) also plays a key role in DISC by mediating the recruitment of several factors that control gene silencing. Recent evidence shows that the FBXL10-RNF68-RNF2 (FRRUC) ubiquitin ligase complex is recruited to DNA lesions in a PARP1-dependent manner and mediates BMI1 recruitment and H2AK119 ubiquitination at break sites [[7\]](#page-9-0). PARP1 also modulates the recruitment of the chromatin reader Chromodomain Y like 1 (CDYL1) to DSBs, which in turn favours the PRC2 subunit EZH2 assembly at DSBs (Fig. [1](#page-1-0) panel 4). EZH2 then catalyses H3K27me3 deposition, inducing DISC [\[33,34\]](#page-10-0). Finally, also the Remodelling and Spacing Factor 1 (RSF1), a component of the chromatin assembly complex RSF [[35](#page-10-0)], regulates transcription [\[36\]](#page-10-0) by promoting HDAC1 association to DSBs, to remove the H2AK118ac modification (Fig. [1](#page-1-0) panel 5), which inhibits H2AK119ub1 deposition and DNA repair [[37](#page-10-0)]. For a schematic overview of the factors involved in DISC see Table [2.](#page-5-0)

By dampening pre-existing transcription upon DNA damage generation, all these mechanisms cooperate to allow a switch between genome expression and its repair. Of note, unperturbed transcription in the presence of DSBs is associated with persistent DNA

damage, increased chromosome aberrations and genome instability [[7,28,31](#page-9-0)–33], further strengthening the intimate relationship between DISC and proper DSB repair.

# Biogenesis and functions of non-coding RNAs at damaged chromatin

As described above, pre-existing transcription is halted in response to local DNA damage [[1,3,38,39\]](#page-9-0). However, various evidence suggest that de novo synthesis of RNA is induced at sites of DNA damage [\[40](#page-10-0)–44]. Why should cells initiate a transcription process, which is both energetically and materially demanding, when their genetic products are at risk of being irremediably compromised by a genotoxic insult? Actually, and more intriguingly, nascent transcripts generated at the damaged chromatin have been proposed to facilitate both the detection and repair of the DNA lesion, ultimately improving cell's ability to preserve genome integrity. For instance, it has been shown that the formation of a DSB is sufficient to recruit RNAPII, Mediator and different components of the Pre-Initiation Complex (PIC), which drives the synthesis of long non-coding RNAs (lncRNAs), hence called damage-induced lncRNAs (dilncRNAs) [[44](#page-11-0)]. These transcripts, normally few hundreds bases long, are not abundantly expressed and are largely retained chromatin-bound. Nevertheless, dilncRNAs can be further processed by DROSHA and DICER to generate smaller molecules, named DNA Damage response RNAs (DDRNAs) (Fig. [1](#page-1-0) panel 6), that, via base-pairing with their longer precursors, cooperate in the gathering of DDR and repair factors at the sites of damage [[43](#page-11-0)–[46\]](#page-11-0). In particular, these ncRNAs, are believed to promote the assembly at DSBs of 53BP1 foci, an important factor involved in DNA damage repair by NHEJ and induce a liquid–liquid phase separation (LLPS) in these 53BP1:RNA complexes [[44](#page-11-0)]. Interestingly, sequence-specific disruption of dilncRNA/ DDRNA functions, through sequence specific antisense oligonucleotides (ASOs) (Fig. [2\)](#page-7-0), impact on DDR signalling and LLPS of 53BP1 foci, a fact that has been shown to contrast the resolution of DSBs as measured by comet assay [\[42](#page-11-0)–46]. Conversely, pharmacological treatment with enoxacin, a small molecule that enhances DICER activity [\[47\]](#page-11-0), can stimulate DDRNA production, and favours a faster and a more accurate DSB repair by NHEJ [\[48](#page-11-0)–50]. Small ncRNAs have also been observed to be generated by RNAPII in proximity to chromatin regions that are prone to form R-loop structures [\[51\]](#page-11-0). Such molecules, named single-stranded DNA-damage-associated small RNAs (sdRNAs),

<span id="page-5-0"></span>



mediate the assembly of BRCA1 repair complex and are required for efficient resolution of DNA single-strand breaks (SSBs) that may arise at RNAPII

termination sites [\[51\]](#page-11-0). Interestingly, RNAPII is not alone in participating in genome protection. In fact, DSB formation can also drive RNA Polymerase III

Factor	Function in ncRNAs de novo synthesis	References
<b>DICER</b>	Processes dilncRNAs to generate shorter DNA Damage RNAs (DDRNAs).	[45, 46]
<b>DROSHA</b>	Processes dilncRNAs to generate shorter DNA Damage RNAs (DDRNAs).	[45, 46]
RNA polymerase II (RNAPII)	Generates damage-induced long non-coding RNAs (dilncRNAs) at DSBs.	[43, 44]
RNA polymerase III (RNAPIII)	Catalyses the synthesis of ncRNAs that form hybrids with the DNA template to allow HR repair.	[40]

**Table 3.** List of factors involved in *de novo* synthesis of ncRNAs at damaged DNA and their functions.

(RNAPIII) transcription [\[40\]](#page-10-0). RNAPIII has been found to be recruited at DSBs, whereby it catalyses the synthesis of ncRNAs that form hybrids with the DNA template [\[40\]](#page-10-0). Such RNA–DNA hybrids, in turn, stimulate the association of components of the HR repair machinery on the chromatin, ultimately fostering DNA damage resolution [[40](#page-10-0)]. Similarly, RNAPII-transcribed dilncRNAs, which form RNA–DNA hybrids at damaged sites during S/G2 phase, are also able to recruit BRCA1, BRCA2 and RAD51 and mediate repair by HR [\[52\]](#page-11-0). For a schematic list of factors involved in de novo transcription at DSBs see Table 3.

A role for damage-induced ncRNAs in modulating transcription at the broken chromatin has been recently proposed [\[22,53\]](#page-10-0). For instance, in our preprint we showed that dilncRNAs regulate DISC and DNA repair by interacting with BMI1 upon DNA damage induction, thus promoting its association at DSBs [[22](#page-10-0)]. This suggests that the newly synthetized ncRNAs act as early DNA damage responders that promote the subsequent PRC1 association at DSBs to silence pre-existing transcription, ultimately favouring repair (Fig. [1](#page-1-0) panel 7). Such findings further expand the range of functions played by ncRNAs generated at damaged chromatin in the maintenance of genome integrity.

#### Targeting DISC at DSB to modulate DNA repair in neurodegeneration and cancer

The interdependency between DSB repair and transcriptional repression of break-bearing and breakflanking genes is emerging as a prominent read out of DDR activation, thus contributing to prevent genome instability and ultimately carcinogenesis onset. Several factors involved in DSB-induced gene silencing have been shown to sustain DSB repair, via both the NHEJ or the HR pathways [\[54\]](#page-11-0). Indeed, factors involved in DISC are often altered in different types of tumours. For instance, the BAF180 subunit of the PBAF complex is mutated in 38% of renal clear cell carcinomas [\[55\]](#page-11-0), EZH2 exhibits gain-of-function mutations in B

cell lymphomas [\[33,56\]](#page-10-0), while the FBXL10 subunit of the FRRUC complex is found upregulated in 14% of invasive breast carcinomas [\[7](#page-9-0)]. Therefore, their targeting can represent an attractive pharmacological strategy in cancer therapy. As an example, cancers harbouring a specific mutation in the repressive factor STAG2 exhibit HR deficiency (HRD) [[32](#page-10-0)]. This so called "BRCAness" phenotype is usually synthetically lethal to the chemotherapeutic drugs targeting the functioning of Poly-ADP polymerases, acting upstream in the cellular response to DNA breaks, such as the PARP1 inhibitor Olaparib [\[57](#page-11-0)]. Therefore, the modulation of DISC may render these and other types of tumours more susceptible to PARP inhibitors, expanding treatment options or increasing their efficacy.

As mentioned above, de novo RNA transcription and processing at DSB sites may play a role in DISC, too [\[22\]](#page-10-0). Moreover, pharmacological modulation of DDRNA biogenesis through enoxacin administration, already known to enhance DNA repair efficiency [[48](#page-11-0)], can stimulate DSB-induced transcriptional silencing, representing an additional opportunity for a targeted cancer therapy. Low doses of enoxacin stimulate DDRNA production without altering miRNA levels, and boost DDR signalling resulting in a more proficient repair by NHEJ [\[48\]](#page-11-0). We have recently shown in our preprint that enoxacin also enhances DSB-induced gene silencing [\[22\]](#page-10-0), connecting DISC to the DDRNA pathway and suggesting the potential use of enoxacin to reinforce repair via NHEJ in pathological contexts. On one hand, enoxacin could be used in terminally differentiated cells, where only NHEJ pathway is accessible, to reduce cell death due to aberrant accumulation of DNA damage. For example, enoxacin treatment could promote survival of differentiated motor neurons in the context of Amyotrophic Lateral sclerosis (ALS) pathology, where growing evidence links DNA damage accumulation to FUS and TDP-43 ALS phenotypes [\[58\]](#page-11-0). Indeed, enoxacin at high doses, by restoring DICER function and microRNA processing, has been shown to increase neuromuscular functions in mouse models of ALS, despite little impact on lifespan [[59](#page-11-0)]. On the other hand, enoxacin could be employed

<span id="page-7-0"></span>![](_page_7_Figure_2.jpeg)

Fig. 2. Site-specific DDR modulation via antisense oligonucleotides (ASOs). Upon generation of a DNA double strand break (DSB) (lightning), damage-induced long non-coding RNAs (dilncRNAs) are transcribed from the break, stimulating the recruitment or the activation of DNA damage response (DDR) factors and the formation of a DDR focus at the site of damage. Inhibitors targeting the activity of DDR factors, such as ATM inhibitors (ATMi, bottom left panel), simultaneously switches off the DDR signalling of all DSBs present in the genome. In contrast, the treatment with site-specific antisense oligonucleotides (ASOs, bottom right panel) targeting dilncRNAs, might inhibit DDR in a sequence-specific manner. The figure was created with [BioRender.com.](http://biorender.com)

in cancer therapy to shift the balance between NHEJ and HR pathways and restore NHEJ-dependent control of unscheduled HR. In fact, resistance to PARPi can arise after a relatively short period of time in the treatment of HRD tumours due to secondary mutations in NHEJ factors that inhibit DNA end-resection and HR. Thus, enoxacin could be used in combined therapies to boost NHEJ and restore PARPi sensitivity.

### Targeting DDRNA functions with antisense oligonucleotides

The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 system is a powerful genomeediting tool, based on the adaptive immunity of bacteria to viruses, that is nowadays used in different applications, among which cancer treatment [[60,61](#page-11-0)]. Indeed, some CRISPR-Cas9 approaches have been proposed to counteract cancer cells proliferation and viability by

targeting chromosomal rearrangements, such as the Philadelphia chromosome found in patients affected by leukaemia [[62](#page-11-0)–[65\]](#page-11-0) or oncogenes like KRAS that, when mutated, can cause lung, colorectal and pancreatic cancers. It has been shown that Cas9, by introducing DSBs in a complementary DNA sequence, can reduce the expression of the gene products with consequent cancer cell death [[66\]](#page-12-0). However, the accurate repair of Cas9 induced DSBs can compromise the efficacy of the treatment. As introduced above, we have demonstrated that the use of ASOs targeting the dilncRNAs/DDRNAs generated upon damage inhibits the formation of a proper DDR focus and the repair of the DNA lesion (Fig. 2) [[42,43,52,67,68](#page-11-0)]. ASOs are synthetic, short, single-stranded molecules that, through Watson-Crick base pairing, inhibit the functions of target RNAs [[69](#page-12-0)]. To prove their selectivity, we took advantage of a cell line engineered to harbour the recognition site for an endonuclease flanked by arrays of the lac-repressor binding site (Lac) and the tetracycline response element (Tet) where we monitored the efficient generation of DSBs through the detection of  $\gamma$ H2AX foci by immunofluorescence. The treatment with ASOs against the RNAs transcribed at Tet loci upon damage revealed an impairment in DDR activation, as monitored by 53BP1 foci formation, specifically at Tet loci, while leaving DDR activation at the Lac sites within the same cell unaffected [\[43\]](#page-11-0). To explore the impact of DDR inactivation by ASOs on DNA repair, we exploited the use of a traffic light reporter system (TLR) to evaluate by flowcytometry the repair pathway choice upon DSBs induction [[70](#page-12-0)]. In fact, depending on the repair mechanism employed, this system generates two different fluorescent proteins: either a functional green fluorescent protein (GFP) in case of HR or a mCherry protein in case of NHEJ [\[70\]](#page-12-0). ASOs against the dilncRNAs transcribed after DSBs generation caused a significant reduction of both the green and the red fluorescent signals, suggesting that ASOs can interfere with both HR and NHEJ [\[52\]](#page-11-0).

The detection of dilncRNAs and DDRNAs synthesis upon DNA damage has been extended also to telomeres, the end of linear chromosomes [\[42,67,68\]](#page-11-0). Our group, in fact, reported that either uncapped or damaged telomeres lead to the synthesis, accumulation, and processing of telomeric dilncRNAs (tdilncRNAs) and tDDRNAs arising from telomeric DNA ends, promoting DDR proteins recruitment and telomeric DNA damage repair [[42,71](#page-11-0)]. Telomere dysfunction has been linked to cellular senescence [\[72\]](#page-12-0), ageing [[73](#page-12-0)], degenerative disorders [\[74\]](#page-12-0) and cancer [\[75\]](#page-12-0). An example is the Hutchinson-Gilford progeria syndrome (HGPS), a premature ageing disorder caused by mutations in the Lamin A (LMNA) gene, resulting in the translation of a truncated lamin A protein called progerin, with consequent chromosomal instability, telomere dysfunction and cellular senescence [\[67\]](#page-12-0). Our laboratory reported elevated levels of tdilncRNAs and tDDRNAs in HGPS patient fibroblasts and in an in vivo HGPS skin mouse model. Importantly, ASOs against tdilncRNAs and tDDRNAs molecules block DDR activation at telomeres, attenuate the detrimental progerin-driven defects, such as senescence, and extend lifespan in HGPS mice [\[67\]](#page-12-0). Another context where we have delineated the role of tdilncRNAs/ tDDRNAs is the alternative lengthening of telomeres (ALT) mechanism, activated by  $\sim$ 10–15% of cancers and characterized by telomeric damage [[68](#page-12-0)]. ALT cancer cells, in fact, display higher levels of these transcripts, compared to non-ALT cells, that are essential for their survival. In fact, inhibition of C-rich tdilncR-NAs with ASOs leads to apoptosis selectively in ALT cells [\[68\]](#page-12-0).

Interestingly, some ASOs have already been approved and are on the market to cure human diseases. In addition, nearly 50 additional ASOs are in clinical trials for the treatment of many diseases [[76](#page-12-0)]. Thus, ASOs are promising candidates as sequencespecific DSB repair inhibitors. Excitingly, also Cas9-based strategies are now in clinical trials to treat genetic diseases and recently the U.S. Food and Drug Administration (FDA) approved two treatments for sickle cell disease ([https://www.fda.gov/news-events/](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease) [press-announcements/fda-approves-first-gene-therapies](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease)[treat-patients-sickle-cell-disease](https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease)). Based on these results, it is tempting to speculate that in the future the combination of Cas9 and ASOs could be used as a precision cancer therapy approach. More specifically, a sgRNA could be designed to target an oncogene, such as the Philadelphia chromosome mentioned before, to introduce a sequence-specific DSB. Upon the generation of site-specific DNA damage by CRISPR-Cas9 at genetic loci altered in the cancer clone, ASOs against dilncRNAs and DDRNAs could be designed to inhibit the signalling and the repair of the sole DSB generated in cancer cell, thus potentially killing them, while sparing the other cells that miss the target (Fig. [2\)](#page-7-0). Importantly, in our preprint we also show that sequence-specific ASOs can also dampen DISC [\[22](#page-10-0)], thus contributing in this way to inhibit restoration of the functionality of the targeted genomic locus. In the same preprint we also observe that targeting dilncR-NAs reduces BMI1 association with damaged chromatin, thus allowing persistent pre-existing gene transcription even upon DSB induction [\[22\]](#page-10-0). Similarly, the CRISPR-Cas13 system can be used to target single strand RNAs [[77](#page-12-0)], and in our preprint it was shown to efficiently inhibit DISC by cleaving dilncRNAs generated at a DSB in an endogenous non-repetitive locus [[22](#page-10-0)]. Thus, by inhibiting DNA repair in a cell-specific and sequence-specific manner, ASOs, CRISPR-Cas9 and CRISPR-Cas13 approaches could be implemented for killing cancer cells more and more precisely, paving the way for a new class of potent, safe and personalized cancer treatments (Fig. [2\)](#page-7-0).

#### Concluding remarks

In this review, we aimed at highlighting the sophisticated interplay at sites of DNA damage between canonical gene transcription, non-coding RNAs local synthesis and chromatin modifiers, emphasizing how they coordinate each other to regulate the traffic dynamics between transcription and repair. Achieving a comprehensive understanding of these intricate processes, their mutual interactions, and regulatory <span id="page-9-0"></span>mechanisms, could significantly contribute to design therapeutic intervention in various contexts, including the development of locus precision targeting in cancer and innovative therapeutic strategies for the treatment of neurodegenerative diseases.

## Acknowledgements

SF was supported by AriSLA (projects "DDRNA&ALS" and its follow up "DDR&ALS"); grant POR FESR 2014–2020; Regione Lombardia (InterSLA project) and by PNRR-CN3 "Centro Nazionale per lo sviluppo di terapia genica e farmaci con tecnologia a RNA". SM was supported by IUSS Pavia. FE was supported by an AIRC fellowship for Italy. ST was supported by PNRR-CN3 "Centro Nazionale per lo sviluppo di terapia genica e farmaci con tecnologia a RNA". UG was supported by PRIN-MIUR 2020 and Istituto Superiore di Sanita RIPREI2023\_7c8ae10d783c. Open access publishing facilitated by Consiglio Nazionale delle Ricerche, as part of the Wiley - CRUI-CARE agreement.

# Author contributions

SM wrote the paragraph entitled "DNA damageinduced transcriptional silencing" and prepared the figures and tables. UG wrote the paragraph entitled "Biogenesis and functions of non-coding RNAs at damaged chromatin", FE wrote the paragraph entitled "Targeting DISC at DSB to modulate DNA repair in neurodegeneration and cancer". ST wrote the paragraph entitled "Targeting DDRNA functions with antisense oligonucleotides". SF conceived the content of the review, wrote the abstract and the title, coordinated the work of the authors and corrected all paragraphs. All authors edited the text and commented on the figures.

## References

- 1 Iannelli F, Galbiati A, Capozzo I, Nguyen Q, Magnuson B, Michelini F, D'Alessandro G, Cabrini M, Roncador M, Francia S et al. (2017) A damaged genome's transcriptional landscape through multilayered expression profiling around in situ-mapped DNA double-strand breaks. Nat Commun 8, 1–12.
- 2 Capozzo I, Iannelli F, Francia S and d'Adda di Fagagna F (2017) Express or repress? The transcriptional dilemma of damaged chromatin. FEBS J 284, 2133–2147.
- 3 Shanbhag NM, Rafalska-Metcalf IU, Balane-Bolivar C, Janicki SM and Greenberg RA (2010) An ATMdependent transcriptional silencing program is

transmitted through chromatin in cis to DNA double strand breaks. Cell 141, 970.

- 4 Pankotai T, Bonhomme C, Chen D and Soutoglou E (2012) DNAPKcs-dependent arrest of RNA polymerase II transcription in the presence of DNA breaks. Nat Struct Mol Biol 19, 276–282.
- 5 Caron P, Pankotai T, Wiegant WW, Tollenaere MAX, Furst A, Bonhomme C, Helfricht A, de Groot A, Pastink A, Vertegaal ACO et al. (2019) WWP2 ubiquitylates RNA polymerase II for DNA-PKdependent transcription arrest and repair at DNA breaks. Genes Dev 1, 684–704.
- 6 Sanchez A, De Vivo A, Uprety N, Kim J, Stevens SM and Kee Y (2016) BMI1-UBR5 axis regulates transcriptional repression at damaged chromatin. Proc Natl Acad Sci USA 113, 11243–11248.
- 7 Rona G, Roberti D, Yin Y, Pagan JK, Homer H, Sassani E, Zeke A, Busino L, Rothenberg E and Pagano M (2018) PARP1-dependent recruitment of the FBXL10-RNF68-RNF2 ubiquitin ligase to sites of DNA damage controls H2A.Z loading. Elife 7, e38771.
- 8 Blackford AN and Jackson SP (2017) ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell 66, 801–817.
- 9 Paull TT (2015) Mechanisms of ATM activation. Annu Rev Biochem 84, 711–738.
- 10 Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ and Jackson SP (2005) MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123, 1213–1226.
- 11 Nowsheen S, Aziz K, Aziz A, Deng M, Qin B, Luo K, Jeganathan KB, Zhang H, Liu T, Yu J et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20, 455–464.
- 12 Mattiroli F, Vissers JHA, van Dijk WJ, Ikpa P, Citterio E, Vermeulen W, Marteijn JA and Sixma TK (2012) RNF168 ubiquitinates K13-15 on H2A/H2AX to drive DNA damage signaling. Cell 150, 1182-1195.
- 13 Chan HL and Morey L (2019) Emerging roles for polycomb-group proteins in stem cells and cancer. Trends Biochem Sci 44, 688–700.
- 14 Tamburri S, Lavarone E, Fernández-Pérez D, Conway E, Zanotti M, Manganaro D and Pasini D (2020) Histone H2AK119 mono-ubiquitination is essential for Polycomb-mediated transcriptional repression. Mol Cell 77, 840–856.e5.
- 15 Liu R, Peng Y, Du W, Wu Y, Zhang W, Hu C, Liu M, Liu X, Wu J, Sun J et al. (2023) BMI1 fine-tunes gene repression and activation to safeguard undifferentiated spermatogonia fate. Front Cell Dev Biol 11, 1146849.
- 16 Yoo J-Y, Choi K-C, Kang H, Kim YJ, Lee J, Jun WJ, Kim M-J, Lee Y-H, Lee O-H and Yoon H-G (2010) Histone deacetylase 3 is selectively involved in

<span id="page-10-0"></span>L3MBTL2-mediated transcriptional repression. FEBS Lett 584, 2225–2230.

- 17 Meng C, Liao J, Zhao D, Huang H, Qin J, Lee T-L, Chen D, Chan W-Y and Xia Y (2019) L3MBTL2 regulates chromatin remodeling during spermatogenesis. Cell Death Differ 26, 2194–2207.
- 18 Qin J, Whyte WA, Anderssen E, Apostolou E, Chen HH, Akbarian S, Bronson RT, Hochedlinger K, Ramaswamy S, Young RA et al. (2012) The polycomb group protein L3mbtl2 assembles an atypical PRC1 family complex that is essential in pluripotent stem cells and early development. Cell Stem Cell 11, 319.
- 19 Bartocci C, Diedrich JK, Ouzounov I, Li J, Piunti A, Pasini D, Yates JR and Lazzerini Denchi E (2014) Isolation of chromatin from dysfunctional telomeres reveals an important role for Ring1b in NHEJmediated chromosome fusions. Cell Rep 7, 1320–1332.
- 20 Chandler H, Patel H, Palermo R, Brookes S, Matthews N and Peters G (2014) Role of polycomb group proteins in the DNA damage response – a reassessment. PLoS One 9, e102968.
- 21 Ismail IH, Andrin C, McDonald D and Hendzel MJ (2010) BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 191, 45– 60.
- 22 Esposito F, Capozzo I, Modafferi S, Gioia U, Manfredi L, Iannelli F, Colantoni A, Riccardi A, di Lillo A, Tavella S et al. (2024) DROSHA, DICER and damageinduced long ncRNA control BMI1-dependent transcriptional repression at DNA double-strand break. bioRxiv. doi: [10.1101/2024.08.07.606960](https://doi.org/10.1101/2024.08.07.606960)
- 23 Fitieh A, Locke AJ, Mashayekhi F, Khaliqdina F, Sharma AK and Ismail IH (2022) BMI-1 regulates DNA end resection and homologous recombination repair. Cell Rep 38, 110536.
- 24 Yang B, Han N, Sun J, Jiang H and Xu H-Y (2019) CtIP contributes to non-homologous end joining formation through interacting with ligase IV and promotion of TMZ resistance in glioma cells. Eur Rev Med Pharmacol Sci 23, 2092–2102.
- 25 Quennet V, Beucher A, Barton O, Takeda S and Löbrich M  $(2011)$  CtIP and MRN promote nonhomologous end-joining of etoposide-induced DNA double-strand breaks in G1. Nucleic Acids Res 39, 2144–2152.
- 26 Jeronimo C and Robert F (2022) The histone chaperone FACT: a guardian of chromatin structure integrity. Transcription 13, 16–38.
- 27 de Vivo A, Sanchez A, Yegres J, Kim J, Emly S and Kee Y (2019) The OTUD5–UBR5 complex regulates FACT-mediated transcription at damaged chromatin. Nucleic Acids Res 47, 729–746.
- 28 Dong C, West KL, Tan XY, Li J, Ishibashi T, Yu C, Sy SMH, Leung JWC and Huen MSY (2020) Screen identifies DYRK1B network as mediator of

transcription repression on damaged chromatin. Proc Natl Acad Sci USA 117, 17019–17030.

- 29 Di Nisio E, Lupo G, Licursi V and Negri R (2021) The role of histone lysine methylation in the response of mammalian cells to ionizing radiation. Front Genet 12, 639602.
- 30 Gong F and Miller KM (2019) Histone methylation and the DNA damage response. Mutat Res Rev Mutat Res 780, 37–47.
- 31 Hu K, Li Y, Wu W, Xie L, Yan H, Cai Y, Chen D, Jiang Q, Lin L, Chen Z et al. (2020) ATM-dependent recruitment of BRD7 is required for transcriptional repression and DNA repair at DNA breaks flanking transcriptional active regions. Adv Sci 7, 2000157.
- 32 Meisenberg C, Pinder SI, Hopkins SR, Wooller SK, Benstead-Hume G, Pearl FMG, Jeggo PA and Downs JA (2019) Repression of transcription at DNA breaks requires cohesin throughout interphase and prevents genome instability. Mol Cell 73, 212-223.e7.
- 33 Abu-Zhayia ER, Awwad SW, Ben-Oz BM, Khoury-Haddad H and Ayoub N (2018) CDYL1 fosters double-strand break-induced transcription silencing and promotes homology-directed repair. J Mol Cell Biol 10, 341–357.
- 34 Chen Z and Tyler JK (2022) The chromatin landscape channels DNA double-strand breaks to distinct repair pathways. Front Cell Dev Biol 10, 909696.
- 35 Loyola A (2003) Histone deposition and chromatin assembly by RSF. Methods 31, 96–103.
- 36 LeRoy G (1998) Requirement of RSF and FACT for transcription of chromatin templates in vitro. Science 282, 1900–1904.
- 37 Min S, Lee HS, Ji JH, Heo Y, Kim Y, Chae S, Choi YW, Kang HC, Nakanishi M and Cho H (2021) The chromatin remodeler RSF1 coordinates epigenetic marks for transcriptional repression and DSB repair. Nucleic Acids Res 49, 12268–12283.
- 38 Ji JH, Min S, Chae S, Ha GH, Kim Y, Park YJ, Lee CW and Cho H (2019) De novo phosphorylation of H2AX by WSTF regulates transcription-coupled homologous recombination repair. Nucleic Acids Res 47, 6299–6314.
- 39 Ui A, Nagaura Y and Yasui A (2015) Transcriptional elongation factor ENL phosphorylated by ATM recruits polycomb and switches off transcription for DSB repair. Mol Cell 58, 468-482.
- 40 Liu S, Hua Y, Wang J, Li L, Yuan J, Zhang B, Wang Z, Ji J and Kong D (2021) RNA polymerase III is required for the repair of DNA double-strand breaks by homologous recombination. Cell 184, 1314–1329.e10.
- 41 Bonath F, Domingo-Prim J, Tarbier M, Friedländer MR and Visa N (2018) Next-generation sequencing reveals two populations of damage-induced small RNAs at endogenous DNA double-strand breaks. Nucleic Acids Res 46, 11869.
- <span id="page-11-0"></span>42 Rossiello F, Aguado J, Sepe S, Iannelli F, Nguyen Q, Pitchiaya S, Carninci P and d'Adda di Fagagna F (2017) DNA damage response inhibition at dysfunctional telomeres by modulation of telomeric DNA damage response RNAs. Nat Commun 8, 13980.
- 43 Michelini F, Pitchiaya S, Vitelli V, Sharma S, Gioia U, Pessina F, Cabrini M, Wang Y, Capozzo I, Iannelli F et al. (2017) Damage-induced lncRNAs control the DNA damage response through interaction with DDRNAs at individual double-strand breaks. Nat Cell Biol 19, 1400–1411.
- 44 Pessina F, Giavazzi F, Yin Y, Gioia U, Vitelli V, Galbiati A, Barozzi S, Garre M, Oldani A, Flaus A et al. (2019) Functional transcription promoters at DNA double-strand breaks mediate RNA-driven phase separation of damage-response factors. Nat Cell Biol 21, 1286–1299.
- 45 Francia S, Cabrini M, Matti V, Oldani A and d'Adda di Fagagna F (2016) DICER, DROSHA and DNA damage response RNAs are necessary for the secondary recruitment of DNA damage response factors. J Cell Sci 129, 1468–1476.
- 46 Francia S, Michelini F, Saxena A, Tang D, de Hoon M, Anelli V, Mione M, Carninci P and d'Adda di Fagagna F (2012) Site-specific DICER and DROSHA RNA products control the DNA-damage response. Nature 488, 231–235.
- 47 Zhang Q, Zhang C and Xi Z (2008) Enhancement of RNAi by a small molecule antibiotic enoxacin. Cell Res 18, 1077–1079.
- 48 Gioia U, Francia S, Cabrini M, Brambillasca S, Michelini F, Jones-Weinert CW and d'Adda di Fagagna F (2019) Pharmacological boost of DNA damage response and repair by enhanced biogenesis of DNA damage response RNAs. Sci Rep 9, 6460.
- 49 Juan LS, Freije A, Sanz-Gómez N, Jiménez-Matías B, Pleguezuelos-Manzano C, Sanz JR, de Diego E, Naranjo S, Clevers H and Gandarillas A (2023) DNA damage triggers squamous metaplasia in human lung and mammary cells via mitotic checkpoints. Cell Death Discov 9, 21.
- 50 Paudel B, Jeong S-Y, Martinez CP, Rickman A, Haluck-Kangas A, Bartom ET, Fredriksen K, Affaneh A, Kessler JA, Mazzulli JR et al. (2024) Death induced by survival gene elimination (DISE) correlates with neurotoxicity in Alzheimer's disease and aging. Nat Commun 15, 264.
- 51 Hatchi E, Goehring L, Landini S, Skourti-Stathaki K, DeConti DK, Abderazzaq FO, Banerjee P, Demers TM, Wang YE, Quackenbush J et al. (2021) BRCA1 and RNAi factors promote repair mediated by small RNAs and PALB2–RAD52. Nature 591, 665–670.
- 52 D'Alessandro G, Whelan DR, Howard SM, Vitelli V, Renaudin X, Adamowicz M, Iannelli F, Jones-Weinert CW, Lee M, Matti V et al. (2018) BRCA2 controls

DNA:RNA hybrid level at DSBs by mediating RNase H2 recruitment. Nat Commun 9, 5376.

- 53 Trifault B, Mamontova V, Cossa G, Ganskih S, Wei Y, Hofstetter J, Bhandare P, Baluapuri A, Nieto B, Solvie D et al. (2024) Nucleolar detention of NONO shields DNA double-strand breaks from aberrant transcripts. Nucleic Acids Res 1, 13–14.
- 54 Long Q, Liu Z and Gullerova M (2021) Sweet melody or jazz? Transcription around DNA double-strand breaks. Front Mol Biosci 8, 655786.
- 55 Kakarougkas A, Ismail A, Chambers AL, Riballo E, Herbert AD, Künzel J, Löbrich M, Jeggo PA and Downs JA (2014) Requirement for PBAF in transcriptional repression and repair at DNA breaks in actively transcribed regions of chromatin. Mol Cell 55, 723–732.
- 56 Liu Y, Liu S, Yuan S, Yu H, Zhang Y, Yang X, Xie G, Chen Z, Li W, Xu B et al. (2017) Chromodomain protein CDYL is required for transmission/restoration of repressive histone marks. J Mol Cell Biol 9, 178–194.
- 57 Byrum AK, Vindigni A and Mosammaparast N (2019) Defining and modulating 'BRCAness. Trends Cell Biol 29, 740–751.
- 58 Wang H, Kodavati M, Britz GW and Hegde ML (2021) DNA damage and repair deficiency in ALS/FTD-associated neurodegeneration: from molecular mechanisms to therapeutic implication. Front Mol Neurosci 14, 784361.
- 59 Emde A, Eitan C, Liou L-L, Libby RT, Rivkin N, Magen I, Reichenstein I, Oppenheim H, Eilam R, Silvestroni A et al. (2015) Dysregulated miRNA biogenesis downstream of cellular stress and ALScausing mutations: a new mechanism for ALS. EMBO J 34, 2633–2651.
- 60 Hsu PD, Lander ES and Zhang F (2014) Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262–1278.
- 61 Doudna JA and Charpentier E (2014) The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096.
- 62 Shtivelman E, Lifshitz B, Gale RP and Canaani E (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 550–554.
- 63 De Klein A, Van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J and Stephenson JR (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 300, 765–767.
- 64 Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by Quinacrine fluorescence and Giemsa staining. Nature 243, 290–293.
- 65 Maddalo D and Ventura A (2016) Somatic engineering of oncogenic chromosomal rearrangements: a perspective. Cancer Res 76, 4918–4923.
- <span id="page-12-0"></span>66 Bender G, Fahrioglu Yamaci R and Taneri B (2021) CRISPR and KRAS: a match yet to be made. J Biomed Sci 28, 77.
- 67 Aguado J, Sola-Carvajal A, Cancila V, Rev^echon G, Ong PF, Jones-Weinert CW, Wallen Arzt E, Lattanzi G, Dreesen O, Tripodo C et al. (2019) Inhibition of DNA damage response at telomeres improves the detrimental phenotypes of Hutchinson–Gilford progeria syndrome. Nat Commun 10, 1-11.
- 68 Rosso I, Jones-Weinert C, Rossiello F, Cabrini M, Brambillasca S, Munoz-Sagredo L, Lavagnino Z, Martini E, Tedone E, Garre M et al. (2023) Alternative lengthening of telomeres (ALT) cells viability is dependent on C-rich telomeric RNAs. Nat Commun 14, 1–16.
- 69 Rinaldi C and Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14, 9–22.
- 70 Certo MT, Ryu BY, Annis JE, Garibov M, Jarjour J, Rawlings DJ and Scharenberg AM (2011) Tracking genome engineering outcome at individual DNA breakpoints. Nat Methods 8, 671–676.
- 71 Nguyen Q, Aguado J, Iannelli F, Suzuki AM, Rossiello F, d'Adda di Fagagna F and Carninci P (2018) Target-

enrichment sequencing for detailed characterization of small RNAs. Nat Protoc 13, 768-786.

- 72 D'Adda Di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP and Jackson SP (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194–198.
- 73 Griffith JD, Comeau L, Rosenfield S, Stansel RM, Bianchi A, Moss H and de Lange T (1999) Mammalian telomeres end in a large duplex loop. Cell 97, 503–514.
- 74 Armanios M and Blackburn EH (2012) The telomere syndromes. Nat Rev Genet 13, 693-704.
- 75 Cesare AJ, Kaul Z, Cohen SB, Napier CE, Pickett HA, Neumann AA and Reddel RR (2009) Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions. Nat Struct Mol Biol 16, 1244–1251.
- 76 Crooke ST, Baker BF, Crooke RM and Liang X-H (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20, 427–453.
- 77 Gupta R, Ghosh A, Chakravarti R, Singh R, Ravichandiran V, Swarnakar S and Ghosh D (2022) Cas13d: a new molecular scissor for transcriptome engineering. Front Cell Dev Biol 10, 866800.